<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004946.pub2" GROUP_ID="PREG" ID="675404032415400061" MERGED_FROM="" MODIFIED="2008-02-05 15:33:54 +0100" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-05 14:29:14 +0000" NOTES_MODIFIED_BY="Sonja Henderson" REVIEW_NO="0225" REVMAN_SUB_VERSION="5.0.0 release candidate 2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-02-05 15:33:54 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection</TITLE>
<CONTACT MODIFIED="2008-02-05 15:33:54 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="17731" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Lisa</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hollier</LAST_NAME><EMAIL_1>lisa.m.hollier@uth.tmc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>LBJ General Hospital</ORGANISATION><ADDRESS_1>5656 Kelley Street</ADDRESS_1><CITY>Houston</CITY><ZIP>77026</ZIP><REGION>Texas</REGION><COUNTRY CODE="">USA</COUNTRY><PHONE_1>+44 713 5665983</PHONE_1><FAX_1>+44 713 5664521</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-02-05 15:33:54 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="17731" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Lisa</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hollier</LAST_NAME><EMAIL_1>lisa.m.hollier@uth.tmc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>LBJ General Hospital</ORGANISATION><ADDRESS_1>5656 Kelley Street</ADDRESS_1><CITY>Houston</CITY><ZIP>77026</ZIP><REGION>Texas</REGION><COUNTRY CODE="">USA</COUNTRY><PHONE_1>+44 713 5665983</PHONE_1><FAX_1>+44 713 5664521</FAX_1></ADDRESS></PERSON><PERSON ID="16850" ROLE="AUTHOR"><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Wendel</LAST_NAME><SUFFIX>MD</SUFFIX><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>UT Southwestern Medical Center</ORGANISATION><ADDRESS_1>5323 Harry Hines Boulevard</ADDRESS_1><CITY>Dallas</CITY><ZIP>75390</ZIP><REGION>TX</REGION><COUNTRY CODE="">USA</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-02-05 14:26:25 +0000" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;New studies found and included or excluded: 31/01/07&lt;/p&gt;" NOTES_MODIFIED="2008-02-05 14:26:25 +0000" NOTES_MODIFIED_BY="Sonja Henderson">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="10" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-02-05 14:29:14 +0000" MODIFIED_BY="Sonja Henderson">
<SUMMARY MODIFIED="2008-02-05 14:28:03 +0000" MODIFIED_BY="Sonja Henderson">
<TITLE MODIFIED="2008-02-05 14:28:00 +0000" MODIFIED_BY="Sonja Henderson">Use of antiviral drugs in late pregnancy for reducing the recurrence of genital herpes at labor and birth and reducing the risk of newborn HSV infection</TITLE>
<SUMMARY_BODY MODIFIED="2008-02-05 14:28:03 +0000" MODIFIED_BY="Sonja Henderson">
<P>The incidence of herpes, a sexually transmitted disease, varies across the world. Among pregnant women with herpes, nearly 75% can expect at least one flare-up during their pregnancy. Transmission of the virus from mother to baby typically occurs by direct contact with the virus during birth. It is often recommended that a cesarean should be offered to women with active lesions to reduce the risk of transmission to the baby. In addition, several antiviral agents are available for use both for therapy and for preventing a flare-up. These antiviral drugs include acyclovir, penciclovir, valacyclovir, and famciclovir. The review assessed whether antiviral drugs given to pregnant women with herpes before a recurrence might be effective in reducing transmission to the baby. Seven studies were identified involving 1249 women. Giving antiviral drugs reduces viral shedding and recurrences at labor and birth. They also reduced the use of cesarean, but there is no evidence of reduction in neonatal herpes. Women should also be informed that the risk of the baby getting herpes during birth is low.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Genital herpes simplex virus (HSV) infection is one of the most common viral sexually transmitted infections. The majority of women with genital herpes will have a recurrence during pregnancy. Transmission of the virus from mother to fetus typically occurs by direct contact with virus in the genital tract during birth. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness of antenatal antiviral prophylaxis for recurrent genital herpes on neonatal herpes and maternal recurrences at delivery.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (January 2007), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library 2006, </I>Issue 4), MEDLINE (January 1966 to February 2007) and EMBASE (January 1974 to February 2007; handsearched conference proceedings; reviewed bibliographies of all relevant articles for further references; and contacted experts in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials which assessed the effectiveness of antivirals compared to placebo or no therapy, on neonatal herpes and maternal disease endpoints among pregnant women with genital herpes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently applied study selection criteria and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seven randomized controlled trials (1249 participants) which met our inclusion criteria compared acyclovir to placebo or no treatment (five trials) and valacyclovir to placebo (two trials). The effect of antepartum antiviral prophylaxis on neonatal herpes could not be estimated. There were no cases of symptomatic neonatal herpes in the included studies in either the treatment or placebo groups. Women who received antiviral prophylaxis were significantly less likely to have a recurrence of genital herpes at delivery (relative risk (RR) 0.28, 95% confidence interval (CI) 0.18 to 0.43, I<SUP>2 </SUP>= 0%). Women who received antiviral prophylaxis were also significantly less likely to have a cesarean delivery for genital herpes (RR 0.30, 95% CI 0.20 to 0.45, I<SUP>2</SUP> = 27.3%). Women who received antiviral prophylaxis were significantly less likely to have HSV detected at delivery (RR 0.14, 95% CI 0.05 to 0.39, I<SUP>2</SUP> = 0%). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Women with recurrent genital herpes simplex virus should be informed that the risk of neonatal herpes is low. There is insufficient evidence to determine if antiviral prophylaxis reduces the incidence of neonatal herpes. Antenatal antiviral prophylaxis reduces viral shedding and recurrences at delivery and reduces the need for cesarean delivery for genital herpes. Limited information exists regarding the neonatal safety of prophylaxis. The risks, benefits, and alternatives to antenatal prophylaxis should be discussed with women who have a history and prophylaxis initiated for women who desire intervention. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-02-05 14:29:14 +0000" MODIFIED_BY="Sonja Henderson">
<BACKGROUND>
<P>Genital herpes simplex virus (HSV) infection is one of the most common viral sexually transmitted infections in the United States (US), now affecting an estimated 45 million adolescents and adults (<LINK REF="REF-Corey-2000" TYPE="REFERENCE">Corey 2000</LINK>; <LINK REF="REF-Fleming-1997" TYPE="REFERENCE">Fleming 1997</LINK>). The seroprevalence (the frequency of individuals in a population that have a particular element (as antibodies to HSV) in their blood serum) is higher among women than among men across various populations (<LINK REF="REF-Cowan-2004" TYPE="REFERENCE">Cowan 2004</LINK>; <LINK REF="REF-Wutzler-2000" TYPE="REFERENCE">Wutzler 2000</LINK>). A very large serologic (the science dealing with the immunological properties and actions of serum) study in the US found that approximately 23% of women had serologic evidence of HSV-2 infection (<LINK REF="REF-Xu-2006" TYPE="REFERENCE">Xu 2006</LINK>). The seroprevalence of HSV-2 in western and southern Europe appears to be lower than in northern Europe and North America (<LINK REF="REF-Smith-2002" TYPE="REFERENCE">Smith 2002</LINK>). </P>
<P>Among women with recurrent genital HSV, nearly 75% can expect at least one recurrence during pregnancy, and about 14% of women will have prodromal symptoms (early symptoms indicating the onset of an attack) or clinical recurrence at delivery (<LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>). Transmission of the virus from mother to fetus typically occurs by direct contact with the virus in the genital tract during delivery. The risk of vertical transmission is related to the gestational age at delivery, the presence of maternal antibodies to HSV and the route of delivery (<LINK REF="REF-Baker-1999" TYPE="REFERENCE">Baker 1999</LINK>; <LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>). To reduce neonatal transmission, it is currently recommended that a cesarean delivery be offered to all women with active genital lesions or prodromal symptoms at delivery (<LINK REF="REF-Baker-1999" TYPE="REFERENCE">Baker 1999</LINK>; <LINK REF="REF-NGC-2002" TYPE="REFERENCE">NGC 2002</LINK>). </P>
<P>The estimated incidence of neonatal herpes infection is broad, ranging from 5 to 80 per 100,000 live births (<LINK REF="REF-Kropp-2006" TYPE="REFERENCE">Kropp 2006</LINK>; <LINK REF="REF-Mahnert-2007" TYPE="REFERENCE">Mahnert 2007</LINK>; <LINK REF="REF-Whitley-2007" TYPE="REFERENCE">Whitley 2007</LINK>). Infection can be classified as disseminated disease (25%), central nervous system disease (30%), or disease limited to the skin, eyes, or mouth (45%) (<LINK REF="REF-Whitley-1988" TYPE="REFERENCE">Whitley 1988</LINK>). About 30% of infants with disseminated disease and 4% of infants with CNS disease will die from their infection. Long-term neurologic sequelae occur in about 20% of survivors (<LINK REF="REF-Kimberlin-2001" TYPE="REFERENCE">Kimberlin 2001</LINK>).</P>
<P>There are several antiviral agents that have been used both for therapy and for prophylaxis in the management of women with genital herpes virus infections. Acyclovir and penciclovir are nucleoside analogs. These drugs become active only after initial phosphorylation (addition of a phosphorus group) that is carried out only by viral thymidine kinase (a viral-specific enzyme) (<LINK REF="REF-Elion-1993" TYPE="REFERENCE">Elion 1993</LINK>; <LINK REF="REF-Larsson-1986" TYPE="REFERENCE">Larsson 1986</LINK>). In this way, the drugs become active only in cells that are infected with the herpes virus. In these cells, the phosphorylated drug (nucleoside analog) is incorporated into the replicating viral DNA and this terminates the growth of the DNA chain. Valacyclovir is a prodrug (inactive form) of acyclovir that is rapidly metabolized to acyclovir (<LINK REF="REF-Weller-1993" TYPE="REFERENCE">Weller 1993</LINK>). Famciclovir is converted to penciclovir. Among non-pregnant women, daily oral acyclovir, valacyclovir, and famciclovir have been shown to reduce the frequency of recurrent genital herpes (<LINK REF="REF-Mertz-1988" TYPE="REFERENCE">Mertz 1988</LINK>; <LINK REF="REF-Mertz-1997" TYPE="REFERENCE">Mertz 1997</LINK>; <LINK REF="REF-Reitano-1998" TYPE="REFERENCE">Reitano 1998</LINK>). Additionally, oral valacyclovir has been shown to reduce the risk of symptomatic transmission of genital herpes (<LINK REF="REF-Corey-2004" TYPE="REFERENCE">Corey 2004</LINK>).</P>
<P>Oral antiviral agents are used in pregnancy to treat genital herpes infections. Acyclovir in pregnancy is well tolerated, with minimal fetal drug accumulation (<LINK REF="REF-Haddad-1993" TYPE="REFERENCE">Haddad 1993</LINK>). The Acyclovir in Pregnancy Registry included data from more than 1200 women exposed to acyclovir. No increase in drug-related fetal abnormalities was ascribed to acyclovir, although long-term developmental outcomes were not evaluated (<LINK REF="REF-Stone-2004" TYPE="REFERENCE">Stone 2004</LINK>). </P>
<P>In an effort to reduce neonatal transmission of HSV and to reduce the number of cesarean deliveries performed for genital herpes infections, a number of studies have investigated whether antiviral therapy in the last month of pregnancy would decrease HSV recurrence at delivery among women with genital herpes diagnosed before or during pregnancy (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Stray_x002d_Pedersen-1990" TYPE="STUDY">Stray-Pedersen 1990</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>). The findings of these studies have been controversial: several studies finding evidence of benefit and others finding no reduction in recurrent HSV or cesarean delivery. A previous meta-analysis found reduction in recurrences and cesarean delivery, but did not address adverse effects (<LINK REF="REF-Sheffield-2003" TYPE="REFERENCE">Sheffield 2003</LINK>). Although the American College of Obstetricians and Gynecologists states that the use of acyclovir to suppress recurrent HSV infection in pregnancy is acceptable, some reports note that there are insufficient data to recommend this prophylaxis. (<LINK REF="REF-Baker-1999" TYPE="REFERENCE">Baker 1999</LINK>; <LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>; <LINK REF="REF-Handsfield-1999" TYPE="REFERENCE">Handsfield 1999</LINK>; <LINK REF="REF-IHMF-2003" TYPE="REFERENCE">IHMF 2003</LINK>; <LINK REF="REF-Smith-1998" TYPE="REFERENCE">Smith 1998</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-02-04 15:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>To estimate the effect of prophylactic antiviral medication provided to pregnant women near term on:</P>
<OL>
<LI>the rate of neonatal HSV transmission;</LI>
<LI>the rate of recurrent genital herpes at delivery;</LI>
<LI>the number of cesarean deliveries performed for clinical herpes simplex virus (HSV) recurrences or prodromal symptoms;</LI>
<LI>the prevalence of HSV detection at delivery.</LI>
</OL>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized clinical trials that used antiviral agents (acyclovir, valacyclovir, and famciclovir) in the third trimester of pregnancy as prophylaxis for recurrent genital herpes at delivery. We did not include quasi-randomized trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Pregnant women in third trimester who have been diagnosed with genital herpes infection before or during pregnancy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Oral antiviral medication for prophylaxis for recurrent genital herpes at delivery compared to placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-02-04 14:42:23 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-02-04 14:41:59 +0000" MODIFIED_BY="[Empty name]">
<P>Neonatal herpes</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-02-04 14:42:16 +0000" MODIFIED_BY="[Empty name]">
<P>Proportion of women with recurrent herpes simplex virus (HSV) (diagnosed clinically) at the time of presentation<BR/>Proportion of women undergoing cesarean delivery with HSV as the primary indication<BR/>Prevalence of HSV at the time of delivery (diagnosed by culture or polymerase chain reaction)<BR/>Side effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-02-04 14:48:27 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-02-05 14:29:14 +0000" MODIFIED_BY="Sonja Henderson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (January 2007).</P>
<P>The Cochrane Pregnancy and Childbirth Group's Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>monthly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness search of a further 36 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.</P>
<P>Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.</P>
<P>In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library 2006, </I>Issue 4<I>). </I>We searched MEDLINE from January 1966 to February 2007 and EMBASE from 1974 to February 2007 to generate three subsets of citations. The first used the keywords "acyclovir" and "aciclovir," and all possible suffixes and derivatives of each. A second subset used "pregnancy" as the keyword or "pregnant," "pregnancy," or "delivery" as title words. We combined these two subsets using "AND" with a third subset generated using keywords "Herpes viridae," "herpes genitalis," "herpes simplex," "Herpesviridae," and all possible suffixes and derivatives. We restricted the final analysis to clinical trials.</P>
<P>We handsearched abstracts from the following scientific forums: Society for Maternal-Fetal Medicine (1990 to 2007), Infectious Disease Society for Obstetrics and Gynecology (1990 to 2006), and the Society for Gynecologic Investigation (1990 to 2006). We reviewed bibliographies of all relevant articles for further references and contacted experts in the field.</P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-02-04 14:49:26 +0000" MODIFIED_BY="[Empty name]">
<P>The authors independently reviewed the studies identified by means of the criteria described above. The following data were abstracted onto standardized forms.</P>
<SUBSECTION>
<HEADING LEVEL="3">Methodologic issues</HEADING>
<P>Publication year; years of study; presentation as article or abstract; allocation concealment; blinding of participants; blinding of caregivers; blinding of outcome assessment; completeness of data collection (including loss to follow up and non-compliance); analysis by intent to treat.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical issues</HEADING>
<P>Medication type; dosage and interval; gestational age at initiation of medication; clinical or laboratory diagnosis of herpes infection, or both; definitions of initial, primary, first episode non-primary, and recurrent herpes simplex virus (HSV) infection; HSV detection at delivery via polymerase chain reaction, culture, and clinical examination; cesarean delivery incidence and indications; and neonatal outcomes. Clinical and virologic recurrences on the day of delivery were used for analysis. Side effects included maternal and neonatal toxicities, maternal acceptability of the prophylactic regimen, and maternal anxiety related to the regimen.</P>
<P>The trial quality was assessed and reported according to the Cochrane Reviewers' Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) and the Cochrane Pregnancy and Childbirth Group's Methodological Guidelines (<I>see </I>'Analysis' in the 'Methods used in Reviews' section of the editorial information about the Group (<LINK REF="REF-PCG-2004" TYPE="REFERENCE">PCG 2004</LINK>).</P>
<OL>
<LI>Allocation concealment: scored as adequate, unclear or inadequate.</LI>
<LI>Generation of random allocation sequence: adequate, unclear or inadequate. (This should include both whether the sequence is truly random and whether it is secure, i.e. whether the random allocation is fixed once it has been obtained, or can be changed. For example, tossing a coin gives a random allocation sequence but is not secure because it can be repeated until the desired result is obtained).</LI>
<LI>Binding of participants (yes/no/unclear).</LI>
<LI>Blinding of caregivers (yes/no/unclear).</LI>
<LI>Blinding of outcome assessment (yes/no/unclear).</LI>
<LI>Completeness of data collection, including differential withdrawal of participants or loss to follow up from different groups (less than 5%, 5% to 10%, 10 to 20%, greater than 20%).</LI>
<LI>Analysis of randomized participants in randomized groups.</LI>
</OL>
<P>We used The Cochrane Collaboration's Review Manager software (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>) for the data analysis. We analyzed data by intention to treat. We calculated risk ratios for the outcomes using a fixed-effect model. We evaluated heterogeneity of treatment using the I<SUP>2 </SUP>statistic.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We identified 10 potentially eligible randomized controlled trials (RCTs) from which we excluded three (<I>see</I> 'Characteristics of excluded studies' table). Two studies were not randomized clinical trials (<LINK REF="STD-Kimberlin-1998" TYPE="STUDY">Kimberlin 1998</LINK>; <LINK REF="STD-Scott-1998" TYPE="STUDY">Scott 1998</LINK>) . In the third excluded trial, the methods of randomization were not clear and after correspondence with the primary author, it was apparent that women were not randomized to antiviral treatment or no treatment (<LINK REF="STD-Stray_x002d_Pedersen-1990" TYPE="STUDY">Stray-Pedersen 1990</LINK>). The remaining seven studies with 1249 participants met our inclusion criteria (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>).</P>
<P>The included RCTs compared acyclovir to a placebo or no treatment (<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>) and valacyclovir to placebo (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>). Gravid women were recruited in the United States (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>), England (<LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>) and France (<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>). In one study, women were included only if they had the first episode of genital herpes infection during the index pregnancy (<LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>). The remaining studies included women with a history of genital herpes that antedated pregnancy.</P>
<P>We have described the seven RCTs included in this review in detail in the table of 'Characteristics of included studies', and summarized their main features below.<BR/>
<B>
<BR/>
</B>
<LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>
<BR/>This RCT included gravid women with a first clinical episode of genital herpes during the index pregnancy. Diagnosis was confirmed by a positive genital culture for herpes simplex virus (HSV). Eligible women were randomized to either oral acyclovir 400 mg or an identical placebo thrice daily beginning at 36 weeks' gestation. The primary outcome was reduction in HSV recurrence at delivery. Other assessed outcomes are listed in the table. Neonates were evaluated for vertical transmission using surface cultures, in addition to being followed for development of symptomatic neonatal herpes. The trial was terminated after a planned interim analysis demonstrated a significant difference in the primary outcome.</P>
<P>
<LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>
<BR/>This RCT included 63 gravid women with a history of recurrent genital herpes. Infection was not documented. At one of the centers enrolling just over half the participants, women were required to have experienced at least one symptomatic recurrence during pregnancy. Eligible women were randomized to either oral acyclovir 200 mg or an identical placebo four times daily beginning at 36 weeks' gestation. The primary outcome was reduction in the frequency of caesarean delivery for genital herpes. Other outcomes are described in the table. Neonates were observed for evidence of symptomatic genital herpes infection and followed for one year. The trial was terminated early due to slow enrollment.</P>
<P>
<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>
<BR/>This RCT included 288 gravid women with a history of recurrent genital herpes. Infection was not documented. Women were required to have at least one symptomatic recurrence during pregnancy. Eligible women were randomized to either oral acyclovir 200 mg four times daily beginning at 36 weeks' gestation or no treatment. The primary outcome was reduction in viral shedding at delivery. Other outcomes are described in the table. Neonates were observed for evidence of symptomatic genital herpes infection. <BR/>
<B>
<BR/>
</B>
<LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>
<BR/>This RCT included 234 gravid women with a history of recurrent genital herpes. Infection was not documented. Eligible women were randomized to either oral acyclovir 400 mg or an identical placebo thrice daily beginning at 36 weeks' gestation. The primary outcome was reduction in HSV recurrence at delivery. Other assessed outcomes are listed in the table. Neonates were followed for development of symptomatic neonatal herpes and surface cultures were obtained. The trial was terminated early due to slow enrollment.<BR/>
<B> <BR/>
</B>
<LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>
<BR/>This RCT included 170 gravid women with a history of recurrent genital herpes. The woman's history of infection was confirmed by documentation of seropositivity or genital culture. Women were required to have had a symptomatic recurrence within one year of the pregnancy. Eligible women were randomized to either oral acyclovir 400 mg or an identical placebo thrice daily beginning at 36 weeks' gestation. The primary outcome was reduction in cesarean delivery for HSV recurrence. Other assessed outcomes are listed in the table. Neonates were followed for development of symptomatic neonatal herpes. The trial was terminated early due to slow enrollment.<BR/> <BR/>
<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>
<BR/>This RCT included gravid women with a history of recurrent HSV-2 genital infection. The woman's history of infection was confirmed by documentation of seropositivity for HSV-2 antibody or a previous genital culture positive for HSV-2. Women with a first episode were specifically excluded. Eligible women were randomized to either oral valacyclovir 500 mg or an identical placebo twice daily beginning between 36 and 36 6/7 weeks' gestation. The primary outcome was reduction in HSV recurrence at delivery. Other assessed outcomes are listed in the table. Neonates were evaluated for vertical transmission using both surface cultures and polymerase chain reaction (PCR), in addition to being followed for development of symptomatic neonatal herpes. Neonatal blood samples were obtained for assessment of toxicity.<BR/>
<B>
<BR/>
</B>
<LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>
<BR/>This RCT included 350 gravid women with either initial or recurrent genital herpes. The woman's history of infection was confirmed by documentation of seropositivity along with genital cultures. Eligible women were randomized to either oral valacyclovir 500 mg or an identical placebo twice daily beginning at 36 weeks' gestation. The primary outcome was reduction in cesarean delivery for HSV recurrence. Other assessed outcomes are listed in the table. Neonates were evaluated for vertical transmission using both surface cultures and PCR, in addition to being followed for development of symptomatic neonatal herpes. Neonatal blood samples were obtained in a subset of infants for assessment of toxicity.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Allocation concealment was scored as adequate in six trials (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>) and was not used in one trial (<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>). The generation of the random allocation sequence was adequate in five studies (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>) and unclear in two (<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>). With the exception of one trial that was completely unblinded (<LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>), all other trials blinded participants and providers. The blinding of outcome assessors was unclear in four trials (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>; <LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>) and rated adequate in two trials (<LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>). The loss to follow up was zero or negligible in five studies (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Braig-2001" TYPE="STUDY">Braig 2001</LINK>; <LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>; <LINK REF="STD-Watts-2003" TYPE="STUDY">Watts 2003</LINK>). The loss to follow up was 10% in one trial (<LINK REF="STD-Scott-1996" TYPE="STUDY">Scott 1996</LINK>) and 18% in another (<LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>). In both cases the loss was non-differential and infant outcomes were available in the second trial. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-02-04 14:49:59 +0000" MODIFIED_BY="[Empty name]">
<P>Seven randomized controlled trials (1249 participants) which met our inclusion criteria compared acyclovir to placebo or no treatment (five trials) and valacyclovir to placebo (two trials).</P>
<SUBSECTION>
<HEADING LEVEL="3">Neonatal herpes</HEADING>
<P>The effect of antepartum antiviral prophylaxis on neonatal herpes could not be estimated. There were no cases of symptomatic neonatal herpes in the included studies in either the treatment or placebo groups. Four of the studies reported the results of neonatal surface cultures or polymerase chain reaction (PCR), or both. Three infants had virus detected after delivery, two in treatment groups and one in a placebo group. All infants were asymptomatic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Maternal outcomes</HEADING>
<P>Women who received antiviral prophylaxis were significantly less likely to have a recurrence of genital herpes at delivery (relative risk (RR) 0.28, 95% CI 0.18 to 0.43, I<SUP>2 </SUP>= 0%). Expressed as an absolute risk reduction, antiviral prophylaxis reduced the risk of recurrence by 10.7%. The corresponding number of women who would need to receive antiviral prophylaxis from 36 weeks until delivery to prevent a recurrence at delivery would be 10.</P>
<P>Women who received antiviral prophylaxis were also significantly less likely to have a cesarean delivery for genital herpes (RR 0.30, 95% CI 0.20 to 0.45, I<SUP>2 </SUP>= 27.3%). Expressed as an absolute risk reduction, antiviral prophylaxis reduced the risk of cesarean delivery for genital HSV by 10.1%. The corresponding number of women who would need to receive antiviral prophylaxis from 36 weeks until delivery to prevent a cesarean delivery for herpes would be 10.</P>
<P>Detection of HSV at delivery was assessed in five studies. Results of PCR and culture were combined for the purposes of this analysis. Women who received antiviral prophylaxis were significantly less likely to have HSV detected at delivery (RR 0.14, 95% CI 0.05 to 0.39, I = 0%). Expressed as an absolute risk reduction, antiviral prophylaxis reduced the risk of viral detection at delivery by 5.8%. The corresponding number of women who would need to receive antiviral prophylaxis from 36 weeks until delivery to prevent viral detection at delivery would be 17.</P>
<P>Two of the studies specifically reported maternal side effects associated with the antiviral prophylaxis. Maternal renal function was evaluated in one trial and no differences were reported (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>). Another study reported "no evidence of haematological or biochemical toxicity" (<LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>). Symptoms attributed to the study drug included nausea, vomiting, diarrhea, headache, bitter taste, and skin rash. There were two reports of symptoms in the treatment group and 13 reports in the placebo group (<LINK REF="STD-Brocklehurst-1998" TYPE="STUDY">Brocklehurst 1998</LINK>). No studies assessed maternal acceptability of the intervention or maternal anxiety.</P>
<P>Neonatal side effects were evaluated by two studies. These included oligohydramnios (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>), renal function (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>), serum chemistries (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>), and neutropenia (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>). The mean aspartate aminotransferase (a liver enzyme) was significantly increased in the placebo-exposed infants in one trial (<LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>), but no differences in the number of infants with transaminases (liver enzymes) greater than two standard deviations above the mean were reported in the other trial (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>). Data from complete blood counts were available for 238 infants (123 were exposed to valacyclovir and 115 were exposed to placebo) from two trials (<LINK REF="STD-Andrews-2006" TYPE="STUDY">Andrews 2006</LINK>; <LINK REF="STD-Sheffield-2006" TYPE="STUDY">Sheffield 2006</LINK>). No infants in either treatment or placebo group had white blood cell counts less than 4000/mm<SUP>3</SUP>. There were no significant differences in other neonatal outcomes.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-02-04 14:50:27 +0000" MODIFIED_BY="[Empty name]">
<P>We found insufficient evidence to evaluate the effect of antiviral prophylaxis given to pregnant women with a history of recurrent genital herpes on the incidence of neonatal herpes. There were no cases of neonatal herpes in the seven included trials, which included over 1200 infants. The estimated incidence of neonatal herpes in North America ranges from 5 to 80 per 100,000 live births (<LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>; <LINK REF="REF-Kropp-2006" TYPE="REFERENCE">Kropp 2006</LINK>; <LINK REF="REF-Mahnert-2007" TYPE="REFERENCE">Mahnert 2007</LINK>; <LINK REF="REF-Whitley-2007" TYPE="REFERENCE">Whitley 2007</LINK>). Corresponding to the lower prevalence of herpes simplex virus (HSV) in women outside the United States, the incidence of neonatal herpes is significantly lower in the United Kingdom - estimated at 1.6/100,000 (<LINK REF="REF-Tookey-1996" TYPE="REFERENCE">Tookey 1996</LINK>). Approximately 70% to 80% of infected infants are born to mothers with no reported history of HSV infection (<LINK REF="REF-Tookey-1996" TYPE="REFERENCE">Tookey 1996</LINK>; <LINK REF="REF-Whitley-1988" TYPE="REFERENCE">Whitley 1988</LINK>). Because the outcome of neonatal herpes is expected to be infrequent in this population, the total sample size included in the meta-analysis is inadequate to detect even large relative reductions in neonatal infection. Neutropenia is a recognized, transient complication of acyclovir treatment of neonatal HSV infection (<LINK REF="REF-Kimberlin-2001" TYPE="REFERENCE">Kimberlin 2001</LINK>). Data were available on a limited number of infants, but no adverse fetal/neonatal effects were identified. Continued assessment of the neonatal safety of maternal prophylaxis is important.</P>
<P>Surrogate outcomes are often measured in situations where an important outcome is rare. Samples from mucosal surfaces of neonates in several trials were taken and tested for the presence of HSV both by culture and by polymerase chain reaction. Three infants, two treatment-exposed and one placebo-exposed, had detectable virus. Thus, we did not find evidence that prophylactic antivirals given to pregnant women reduced the frequency of detectable HSV.</P>
<P>Antiviral prophylaxis was associated with a significant reduction in recurrence at the time of delivery. Because the practice of performing a cesarean delivery when women present with active genital herpes is relatively common, there was also a significant reduction in cesarean delivery for genital HSV. These findings are similar to a previous meta-analysis, which included only trials involving the use of acyclovir (<LINK REF="REF-Sheffield-2003" TYPE="REFERENCE">Sheffield 2003</LINK>) and showed significant reductions in recurrence at delivery, cesarean delivery for HSV and in total cesarean deliveries. The effectiveness in reducing recurrences was consistent for acyclovir and for valacyclovir.</P>
<P>Cesarean delivery has been shown to reduce the risk of transmission of HSV to the neonate (<LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>). One potential concern of using prophylactic antivirals would be that suppression of viral activity would be incomplete and women might have asymptomatic shedding rather than an active lesion, and hence would not have a cesarean delivery. In our analysis and in a previous analysis, prophylaxis was effective in significantly reducing the detection of virus at delivery (<LINK REF="REF-Sheffield-2003" TYPE="REFERENCE">Sheffield 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Limitations of the analysis</HEADING>
<P>The major weakness of our review relates to the inherent shortcomings of the original research. Half the trials were stopped before the planned sample sizes were reached. Additionally, the rate of study withdrawal in two large studies was greater than 15%. The withdrawal did appear to be non-differential and neonatal outcomes were available in a significant proportion of women (<LINK REF="STD-Scott-2002" TYPE="STUDY">Scott 2002</LINK>). In this meta-analysis, we combined two different drugs used for prophylaxis and different treatment regimens of one drug (acyclovir). We believe that the similarity in the drugs and the similarity of the treatment effects justifies the evaluation of summary measures.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Women with recurrent genital herpes simplex virus should be informed that the risk of neonatal herpes is low. There is insufficient evidence to determine if antiviral prophylaxis for women with a history of genital herpes reduces the incidence of neonatal herpes. Antenatal antiviral prophylaxis reduces viral shedding and recurrences at delivery and reduces the need for cesarean delivery for genital herpes. Limited information exists regarding the neonatal safety of prophylaxis. The risks, benefits, and alternatives to antenatal prophylaxis should be discussed with women who have a history and prophylaxis initiated in women who desire intervention. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Because neonatal HSV is an infrequent complication in this population, other interventions will be needed to significantly reduce the overall incidence of neonatal herpes. Continued assessment of the safety of antepartum antiviral prophylaxis is important to inform the woman's decision made based on the risks and benefits of the intervention.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the authors of the studies who responded to our requests for additional information and clarification.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by two peers (an editor, and a referee who is external to the editorial team), one or more members of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Dr Wendel has received research funding from Glaxo from 1994 to 2004. Dr Wendel was on the GlaxoSmithKline speakers' bureau for six months in 2006. In 1997, Dr Hollier received honoraria for several local talks sponsored by the makers of Valacyclovir and Famciclovir. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>LM Hollier and GD Wendel reviewed all potential trials and assessed all included trials. LM Hollier wrote the first draft of the review and GD Wendel reviewed it.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-2006" NAME="Andrews 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews W, Kimberlin D, Whitley R, Cliver S, Deeter R</AU>
<TI>Valaciclovir suppressive therapy in pregnant women reduces recurrent genital herpes (hsv): results of a randomized trial [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>6 Pt 2</NO>
<PG>S73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R</AU>
<TI>Valacyclovir therapy to reduce recurrent genital herpes in pregnant women</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>3</NO>
<PG>774-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braig-2001" NAME="Braig 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braig S, Luton D, Sibony O, Edlinger C, Boissinot C, Blot P et al</AU>
<TI>Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brocklehurst-1998" NAME="Brocklehurst 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E, Ellis E et al</AU>
<TI>A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Mindel A</AU>
<TI>Trial to evaluate efficacy and safety of a prophylactic course of orally administered acyclovir vs placebo to prevent viral shedding, herpes lesion development and subsequent need for Caesarean section in pregnant women with genital herpes infection</TI>
<SO>Personal communication</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-1996" NAME="Scott 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr</AU>
<TI>Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>87</VL>
<NO>1</NO>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-2002" NAME="Scott 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Scott LL, Hollier LM, Baum A, Jackson G, Sanchez PJ, Wendel GD=Jr. Prevention of recurrent genital herpes at delivery using acyclovir suppression for herpes infection diagnosed prior to pregnancy - an interim analysis. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 2):S213.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott LL, Hollier LM, Baum A, Jackson G, Sanchez PJ, Wendel GDJr</AU>
<TI>Prevention of recurrent genital herpes at delivery using acyclovir suppression for herpes infection diagnosed prior to pregnancy - an interim analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>S213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr</AU>
<TI>Acyclovir suppression to prevent recurrent genital herpes at delivery</TI>
<SO>Infectious Diseases in Obstetrics and Gynecology</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>2</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheffield-2006" NAME="Sheffield 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheffield JS, Hill J, Laibl V, Hollier LM, Sanchez P, Wendel GD</AU>
<TI>Valacyclovir suppression to prevent recurrent herpes at delivery: a randomized controlled trial [abstract]</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>4 Suppl</NO>
<PG>5S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ et al</AU>
<TI>Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>1</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watts-2003" NAME="Watts 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watts DH, Brown ZA, Money D, Selke S, Aura J, Remple V et al</AU>
<TI>A double-blind randomized, placebo-controlled trial of acyclovir in late pregnancy for reduction of herpes simplex virus (HSV) shedding and cesarean section [abstract]</TI>
<SO>Infectious Diseases in Obstetrics &amp; Gynecology</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>165-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL et al</AU>
<TI>A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>836-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimberlin-1998" NAME="Kimberlin 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimberlin DF, Weller S, Andrews WW, Hauth JC, Whitley RJ, Lakeman F et al</AU>
<TI>Valaciclovir pharmacokinetics in late pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>S12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F et al</AU>
<TI>Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<NO>4</NO>
<PG>846-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-1998" NAME="Scott 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott LL, Hollier LM, Jackson G, Sanchez PJ, Baum A, Wendel GD</AU>
<TI>Acyclovir suppression to prevent cesarean delivery after first episode genital simplex infection</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stray_x002d_Pedersen-1990" NAME="Stray-Pedersen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stray-Pedersen B</AU>
<TI>Acyclovir in late pregnancy to prevent neonatal herpes simplex [letter]</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8717</NO>
<PG>756</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Baker-1999" NAME="Baker 1999" NOTES="&lt;p&gt;Baker DA. Management of herpes in pregnancy. ACOG Practice Bulletin 8. ACOG, Washington, DC, October 1999&lt;/p&gt;" TYPE="BOOK">
<AU>Baker DA</AU>
<SO>Management of herpes in pregnancy. ACOG Practice Bulletin 8</SO>
<YR>October 1999</YR>
<PB>ACOG</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2003" NAME="Brown 2003" NOTES="&lt;p&gt;Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L</AU>
<TI>Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corey-2000" NAME="Corey 2000" NOTES="&lt;p&gt;Corey, L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000;283(6):791-4&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Corey L, Handsfield HH</AU>
<TI>Genital herpes and public health: addressing a global problem</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>6</NO>
<PG>791-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corey-2004" NAME="Corey 2004" TYPE="JOURNAL_ARTICLE">
<AU>Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T et al</AU>
<TI>Once-daily valacyclovir to reduce the risk of transmission of genital herpes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<PG>11-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cowan-2004" NAME="Cowan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA et al</AU>
<TI>Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka</TI>
<SO>Sexually Transmitted Infections</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>4</NO>
<PG>286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elion-1993" NAME="Elion 1993" TYPE="JOURNAL_ARTICLE">
<AU>Elion GB</AU>
<TI>Acyclovir: discovery, mechanism of action, and selectivity</TI>
<SO>Journal of Medical Virology</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleming-1997" NAME="Fleming 1997" NOTES="&lt;p&gt;Fleming, DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME. Herpes simplex virus type 2 in the united states, 1976 to 1994. New England Journal of Medicine 1997;337(16):1105-11&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK et al</AU>
<TI>Herpes simplex virus type 2 in the united states, 1976 to 1994</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>16</NO>
<PG>1105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddad-1993" NAME="Haddad 1993" NOTES="&lt;p&gt;Haddad, J, Langer B, Astruc D, Messer J, Lokiec F. Oral acyclovir and recurrent genital herpes during late pregnancy. Obstetrics &amp;amp; Gynecology 1993;82(1):102-4&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haddad J, Langer B, Astruc D, Messer J, Lokiec F</AU>
<TI>Oral acyclovir and recurrent genital herpes during late pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>1</NO>
<PG>102-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handsfield-1999" NAME="Handsfield 1999" NOTES="&lt;p&gt;Handsfield, HH, Stone KM, Wasserheit JN. Prevention agenda for genital herpes. Sexually Transmitted Diseases 1999;26(4):228-31&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Handsfield HH, Stone KM, Wasserheit JN</AU>
<TI>Prevention agenda for genital herpes</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>4</NO>
<PG>228-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" NOTES="&lt;p&gt;Clarke M, Oxman AD, editors. Cochrane Reviewers&amp;#8217; Handbook 4.2.0 [updated March 2003]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software. Updated quarterly.&lt;br&gt;Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IHMF-2003" NAME="IHMF 2003" NOTES="&lt;p&gt;International Herpes Management Forum (IHMF) Web site. Available at: http://www.ihmf.org. Accessed October 4, 2003&lt;/p&gt;" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>International Herpes Management Forum (IHMF)</TI>
<SO>http://www.ihmf.org</SO>
<YR>(accessed October 4, 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimberlin-2001" NAME="Kimberlin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC et al</AU>
<TI>Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>230-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kropp-2006" NAME="Kropp 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kropp RY, Wong T, Cormier L, Ringrose A, Burton S, Embree JE, et al.</AU>
<TI>Neonatal herpes siimplex virus infections in Canada: results of a 3-year national prospective study.</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>6</NO>
<PG>1955-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-1986" NAME="Larsson 1986" TYPE="JOURNAL_ARTICLE">
<AU>Larsson A, Stenberg K, Ericson AC, Haglund U, Yisak WA, Johansson NE et al</AU>
<TI>Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1986</YR>
<VL>30</VL>
<PG>598-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahnert-2007" NAME="Mahnert 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mahnert N, Roberts SW, Laibl VR, Sheffield JS, Wendel GD Jr.</AU>
<TI>The incidence of neonatal herpes infection</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>5</NO>
<PG>e55-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mertz-1988" NAME="Mertz 1988" TYPE="JOURNAL_ARTICLE">
<AU>Mertz GJ, Jones CC, Mills J, Fife KH, Lemon SM, Stapleton JT et al</AU>
<TI>Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>260</VL>
<NO>2</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mertz-1997" NAME="Mertz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D et al</AU>
<TI>Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>3</NO>
<PG>343-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NGC-2002" NAME="NGC 2002" TYPE="OTHER">
<AU>NGC</AU>
<TI>2002 national guideline for the management of genital herpes</TI>
<SO>www.guideline.gov</SO>
<YR>(accessed 6 March 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PCG-2004" NAME="PCG 2004" TYPE="OTHER">
<TI>The Editorial Team</TI>
<SO>Pregnancy and Childbirth Group. About the Cochrane Collaboration (Collaborative Review Groups (CRGs)) 2004, Issue 3. Art. No.: PREG</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reitano-1998" NAME="Reitano 1998" TYPE="JOURNAL_ARTICLE">
<AU>Reitano M, Tyring S, Lang W, Thoming C, Worm AM, Borelli S et al</AU>
<TI>Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>3</NO>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" NAME="RevMan 2003" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheffield-2003" NAME="Sheffield 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD</AU>
<TI>Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>6</NO>
<PG>1396-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1998" NAME="Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Smith JR, Cowan FM, Munday P</AU>
<TI>The management of herpes simplex virus infection in pregnancy</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>105</VL>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2002" NAME="Smith 2002" TYPE="JOURNAL_ARTICLE">
<AU>Smith JS, Robinson NJ</AU>
<TI>Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>186</VL>
<NO>Suppl 1</NO>
<PG>S3-S28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-2004" NAME="Stone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER et al</AU>
<TI>Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir in pregnancy registry, 1984-1999</TI>
<SO>Birth Defects Research. Part A, Clinical and Molecular Teratology</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>4</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tookey-1996" NAME="Tookey 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tookey P, Peckham CS</AU>
<TI>Neonatal herpes simplex virus infection in the British Isles</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>432-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weller-1993" NAME="Weller 1993" TYPE="JOURNAL_ARTICLE">
<AU>Weller S, Blum MR, Doucette M</AU>
<TI>Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1993</YR>
<VL>54</VL>
<PG>595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitley-1988" NAME="Whitley 1988" TYPE="JOURNAL_ARTICLE">
<AU>Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF et al</AU>
<TI>Changing presentation of herpes simplex virus infection in neonates</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>109-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitley-2007" NAME="Whitley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Whitley R, Davis EA, Suppapanya N.</AU>
<TI>Incidence of neonatal herpes simplex virus infections in a managed-care population</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>9</NO>
<PG>704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wutzler-2000" NAME="Wutzler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wutzler P, Doerr HW, Farber I, Eichhorn U, Helbig B, Sauerbrei A et al</AU>
<TI>Seroprevalence of herpes simplex virus type 1 and type 2 in selected Gernam populations: relevance for the incidence of genital herpes</TI>
<SO>Journal of Medical Virology</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>2</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2006" NAME="Xu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ et al</AU>
<TI>Trends in Herpes Simplex Virus type 1 and type 2 seroprevalence in the United States</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<PG>964-73</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Andrews-2006">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with documented recurrent genital HSV-2 infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Valacyclovir 500 mg po BID vs placebo beginning at 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HSV shedding within 7 days of delivery, active HSV lesions at delivery, cesarean for active HSV, neonatal HSV positive, symptomatic neonatal HSV.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Braig-2001">
<CHAR_METHODS>
<P>Randomized controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with documented recurrent genital herpes infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir 200 mg po 4 times daily or no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cesarean delivery for genital herpes, asymptomatic viral shedding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brocklehurst-1998">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with documented recurrent genital herpes infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir 200 mg po 4 times daily vs placebo from 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical recurrence at time of labor, cesarean delivery for HSV, infants with neonatal herpes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scott-1996">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with first episode genital herpes infection during index pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir 400 mg po TID vs placebo from 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HSV outbreak at delivery, HSV culture at delivery, cesarean delivery for genital HSV, positive neonatal HSV cultures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scott-2002">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with recurrent genital HSV-2 infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir 400 mg po TID vs placebo from 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical HSV recurrence at delivery, cesarean delivery for HSV, HSV culture at delivery, neonatal HSV cultures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sheffield-2006">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with documented recurrent genital HSV-2 infection confirmed with serology.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Valacyclovir 500 mg po BID vs placebo beginning at 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HSV outbreak at delivery, HSV culture and PCR at delivery, cesarean delivery for genital HSV, positive neonatal HSV cultures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Watts-2003">
<CHAR_METHODS>
<P>Randomized double-masked, placebo-controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Gravid women with documented recurrent genital HSV-2 infection confirmed with serology or culture.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir 400 mg po TID vs placebo from 36 weeks' gestation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HSV outbreak at delivery, HSV culture and PCR at delivery, cesarean delivery for herpes, neonatal herpes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BID: dosing twice daily<BR/>HSV: herpes simplex virus<BR/>PCR: polymerase chain reaction<BR/>po: oral dosing<BR/>TID: three times a day<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Kimberlin-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial comparing antiviral to placebo for prophylaxis of recurrent genital herpes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scott-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized trial comparing antiviral to placebo for prophylaxis of recurrent genital herpes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stray_x002d_Pedersen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>After corresponding with the author, it was determined that this study was not a randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Andrews-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Braig-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brocklehurst-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Scott-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Scott-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sheffield-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Watts-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Antenatal antiviral prophylaxis versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="646" TOTAL_2="594" WEIGHT="0.0" Z="0.0">
<NAME>Neonatal herpes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-Andrews-2006" TOTAL_1="57" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-Braig-2001" TOTAL_1="167" TOTAL_2="121" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-Brocklehurst-1998" TOTAL_1="31" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Scott-1996" TOTAL_1="21" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Scott-2002" TOTAL_1="116" TOTAL_2="115" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Sheffield-2006" TOTAL_1="170" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Watts-2003" TOTAL_1="84" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.585826288189744" CI_END="0.42735079337493925" CI_START="0.18448747497573426" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.28078616204973367" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.36921548543822585" LOG_CI_START="-0.7340331131556965" LOG_EFFECT_SIZE="-0.5516242992969611" METHOD="MH" NO="2" P_CHI2="0.5979191656831211" P_Q="0.0" P_Z="3.0824399490110948E-9" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="651" TOTAL_2="598" WEIGHT="100.0" Z="5.927146483483433">
<NAME>Genital herpes simplex virus recurrence at delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.756363860551282" CI_END="0.4295604690507256" CI_START="0.14905001587115282" DF="4.0" EFFECT_SIZE="0.25303358419314714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="58" I2="15.902144636672444" ID="CMP-001.02.01" LOG_CI_END="-0.36697569207355885" LOG_CI_START="-0.8266679733867766" LOG_EFFECT_SIZE="-0.5968218327301678" NO="1" P_CHI2="0.3132218634757602" P_Z="3.594426378244805E-7" STUDIES="5" TAU2="0.0" TOTAL_1="424" TOTAL_2="375" WEIGHT="67.50326502187022" Z="5.089270996661752">
<NAME>Acyclovir</NAME>
<DICH_DATA CI_END="0.38773328825151776" CI_START="0.0014152873402764423" EFFECT_SIZE="0.023425499231950846" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" LOG_CI_END="-0.4114669117001904" LOG_CI_START="-2.8491553780705843" LOG_EFFECT_SIZE="-1.6303111448853873" ORDER="96" O_E="0.0" SE="1.431910271898488" STUDY_ID="STD-Braig-2001" TOTAL_1="167" TOTAL_2="121" VAR="2.0503670267684018" WEIGHT="19.94034899974765"/>
<DICH_DATA CI_END="1.5766602564324415" CI_START="0.07509239210690502" EFFECT_SIZE="0.34408602150537637" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.1977381203088398" LOG_CI_START="-1.1244040607768981" LOG_EFFECT_SIZE="-0.4633329702340291" ORDER="97" O_E="0.0" SE="0.7766328618791105" STUDY_ID="STD-Brocklehurst-1998" TOTAL_1="31" TOTAL_2="32" VAR="0.6031586021505376" WEIGHT="6.55635057814832"/>
<DICH_DATA CI_END="0.9255823558108545" CI_START="0.05376432825998764" EFFECT_SIZE="0.2230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.03358493284522222" LOG_CI_START="-1.269505775970539" LOG_EFFECT_SIZE="-0.6515453544078806" ORDER="98" O_E="0.0" SE="0.7259860211586529" STUDY_ID="STD-Scott-1996" TOTAL_1="26" TOTAL_2="29" VAR="0.5270557029177719" WEIGHT="10.497851658853321"/>
<DICH_DATA CI_END="1.0146824524577864" CI_START="0.18539826562302109" EFFECT_SIZE="0.43372844827586204" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.006330149911705225" LOG_CI_START="-0.7318943329416547" LOG_EFFECT_SIZE="-0.36278209151497476" ORDER="99" O_E="0.0" SE="0.4336367154981891" STUDY_ID="STD-Scott-2002" TOTAL_1="116" TOTAL_2="115" VAR="0.1880408010280574" WEIGHT="17.84250245314264"/>
<DICH_DATA CI_END="1.016518208969224" CI_START="0.11216312041395658" EFFECT_SIZE="0.33766233766233766" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.007115162594348493" LOG_CI_START="-0.9501499169976763" LOG_EFFECT_SIZE="-0.47151737720166387" ORDER="100" O_E="0.0" SE="0.5623022462909215" STUDY_ID="STD-Watts-2003" TOTAL_1="84" TOTAL_2="78" VAR="0.3161838161838162" WEIGHT="12.666211331978293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01467075387513253" CI_END="0.6777873720905389" CI_START="0.16898817881018596" DF="1.0" EFFECT_SIZE="0.33843471103024" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="29" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.16890652679767448" LOG_CI_START="-0.7721436744222202" LOG_EFFECT_SIZE="-0.47052510060994734" NO="2" P_CHI2="0.9035937039280548" P_Z="0.0022315840686931636" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="223" WEIGHT="32.49673497812979" Z="3.057544631159109">
<NAME>Valacyclovir</NAME>
<DICH_DATA CI_END="1.2938102569789292" CI_START="0.10119699425400874" EFFECT_SIZE="0.3618421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.11187058978769154" LOG_CI_START="-0.9948323866887488" LOG_EFFECT_SIZE="-0.4414808984505287" ORDER="101" O_E="0.0" SE="0.6500828066503469" STUDY_ID="STD-Andrews-2006" TOTAL_1="57" TOTAL_2="55" VAR="0.4226076555023923" WEIGHT="9.041418942446471"/>
<DICH_DATA CI_END="0.7542371689889875" CI_START="0.14387001222983747" EFFECT_SIZE="0.32941176470588235" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.12249206926656837" LOG_CI_START="-0.8420297194775785" LOG_EFFECT_SIZE="-0.48226089437207353" ORDER="102" O_E="0.0" SE="0.42265997750275935" STUDY_ID="STD-Sheffield-2006" TOTAL_1="170" TOTAL_2="168" VAR="0.17864145658263303" WEIGHT="23.455316035683314"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.248218810852283" CI_END="0.4538256682009985" CI_START="0.19608908751229348" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2983123550361108" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="83" I2="27.257021939018802" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.3431109442316087" LOG_CI_START="-0.7075465744355462" LOG_EFFECT_SIZE="-0.5253287593335776" METHOD="MH" NO="3" P_CHI2="0.2204764721965935" P_Q="0.0" P_Z="1.5996299009589203E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="651" TOTAL_2="598" WEIGHT="99.99999999999999" Z="5.650520218128755">
<NAME>Cesarean delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.688553409364424" CI_END="0.4619204404320489" CI_START="0.16121691776393599" DF="4.0" EFFECT_SIZE="0.2728908017112609" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="55" I2="53.96241685423899" ID="CMP-001.03.01" LOG_CI_END="-0.33543281937191616" LOG_CI_START="-0.7925893861909443" LOG_EFFECT_SIZE="-0.5640111027814303" NO="1" P_CHI2="0.06937352718150869" P_Z="1.3237052056856698E-6" STUDIES="5" TAU2="0.0" TOTAL_1="424" TOTAL_2="375" WEIGHT="67.29848293568773" Z="4.83616130037973">
<NAME>Acyclovir</NAME>
<DICH_DATA CI_END="0.38773328825151776" CI_START="0.0014152873402764423" EFFECT_SIZE="0.023425499231950846" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" LOG_CI_END="-0.4114669117001904" LOG_CI_START="-2.8491553780705843" LOG_EFFECT_SIZE="-1.6303111448853873" ORDER="103" O_E="0.0" SE="1.431910271898488" STUDY_ID="STD-Braig-2001" TOTAL_1="167" TOTAL_2="121" VAR="2.0503670267684018" WEIGHT="20.789009466214562"/>
<DICH_DATA CI_END="1.5410840286219887" CI_START="0.17285830817275216" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.18782631955678825" LOG_CI_START="-0.7623097419134841" LOG_EFFECT_SIZE="-0.2872417111783479" ORDER="104" O_E="0.0" SE="0.5581146257569953" STUDY_ID="STD-Brocklehurst-1998" TOTAL_1="31" TOTAL_2="32" VAR="0.311491935483871" WEIGHT="9.113851466670026"/>
<DICH_DATA CI_END="0.8605570465041034" CI_START="0.003253094853289601" EFFECT_SIZE="0.05291005291005291" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.06522033491136982" LOG_CI_START="-2.4877032734351183" LOG_EFFECT_SIZE="-1.276461804173244" ORDER="105" O_E="0.0" SE="1.4229784695727918" STUDY_ID="STD-Scott-1996" TOTAL_1="26" TOTAL_2="29" VAR="2.024867724867725" WEIGHT="11.515134700089135"/>
<DICH_DATA CI_END="1.2985072064426486" CI_START="0.24714921800523332" EFFECT_SIZE="0.5665024630541872" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.11344436421529594" LOG_CI_START="-0.6070407593344985" LOG_EFFECT_SIZE="-0.24679819755960125" ORDER="106" O_E="0.0" SE="0.4232165280320299" STUDY_ID="STD-Scott-2002" TOTAL_1="116" TOTAL_2="115" VAR="0.17911222959948597" WEIGHT="16.27664382170688"/>
<DICH_DATA CI_END="1.265766590211201" CI_START="0.09579427179799264" EFFECT_SIZE="0.3482142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.10235362832825269" LOG_CI_START="-1.0186604596156177" LOG_EFFECT_SIZE="-0.4581534156436824" ORDER="107" O_E="0.0" SE="0.6584892243674596" STUDY_ID="STD-Watts-2003" TOTAL_1="84" TOTAL_2="78" VAR="0.43360805860805857" WEIGHT="9.603843481007125"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08362828338291109" CI_END="0.7047980604074907" CI_START="0.17443387887275785" DF="1.0" EFFECT_SIZE="0.3506289484610119" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="28" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.15193529976553602" LOG_CI_START="-0.7583691617281842" LOG_EFFECT_SIZE="-0.45515223074686006" NO="2" P_CHI2="0.7724393992523464" P_Z="0.0032603822221087242" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="223" WEIGHT="32.701517064312256" Z="2.942058600948823">
<NAME>Valacyclovir</NAME>
<DICH_DATA CI_END="1.5185616237998238" CI_START="0.1126132977862802" EFFECT_SIZE="0.41353383458646614" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1814324204447261" LOG_CI_START="-0.94841032339041" LOG_EFFECT_SIZE="-0.38348895147284195" ORDER="108" O_E="0.0" SE="0.6636752205405406" STUDY_ID="STD-Andrews-2006" TOTAL_1="57" TOTAL_2="55" VAR="0.44046479835953517" WEIGHT="8.247943703833686"/>
<DICH_DATA CI_END="0.7542371689889875" CI_START="0.14387001222983747" EFFECT_SIZE="0.32941176470588235" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.12249206926656837" LOG_CI_START="-0.8420297194775785" LOG_EFFECT_SIZE="-0.48226089437207353" ORDER="109" O_E="0.0" SE="0.42265997750275935" STUDY_ID="STD-Sheffield-2006" TOTAL_1="170" TOTAL_2="168" VAR="0.17864145658263303" WEIGHT="24.453573360478572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.135914655552839" CI_END="0.38809738485223216" CI_START="0.050523986029293796" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1400293785256495" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.41105928369150135" LOG_CI_START="-1.2965023936226796" LOG_EFFECT_SIZE="-0.8537808386570904" METHOD="MH" NO="4" P_CHI2="0.8885328948297798" P_Q="0.0" P_Z="1.5698177599709294E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="457" TOTAL_2="430" WEIGHT="100.0" Z="3.779756543790521">
<NAME>Genital herpes simplex virus detection at delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.964225920642598" CI_END="0.44883981885236335" CI_START="0.025546599841940524" DF="3.0" EFFECT_SIZE="0.10708095650184678" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="15" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.34790862158087255" LOG_CI_START="-1.592666894674009" LOG_EFFECT_SIZE="-0.9702877581274407" NO="1" P_CHI2="0.8099073078850088" P_Z="0.0022462588732899487" STUDIES="4" TAU2="0.0" TOTAL_1="339" TOTAL_2="293" WEIGHT="61.87490197766805" Z="3.0555797084107468">
<NAME>Acyclovir</NAME>
<DICH_DATA CI_END="0.9822444029052673" CI_START="0.0031768362560164083" EFFECT_SIZE="0.055860805860805864" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.007780437236729193" LOG_CI_START="-2.498005169479174" LOG_EFFECT_SIZE="-1.2528928033579514" ORDER="110" O_E="0.0" SE="1.4627703345304408" STUDY_ID="STD-Braig-2001" TOTAL_1="167" TOTAL_2="121" VAR="2.1396970515822975" WEIGHT="25.853094670023758"/>
<DICH_DATA CI_END="8.445091578238452" CI_START="0.015441068147078815" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.926604363404716" LOG_CI_START="-1.8113226603256165" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="111" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Scott-1996" TOTAL_1="23" TOTAL_2="25" VAR="2.5865384615384617" WEIGHT="4.943338980861685"/>
<DICH_DATA CI_END="1.3478302770809374" CI_START="0.00439013714406883" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1296352079501289" LOG_CI_START="-2.3575219125638025" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="112" O_E="0.0" SE="1.4609684042161892" STUDY_ID="STD-Scott-2002" TOTAL_1="102" TOTAL_2="102" VAR="2.1344286781179984" WEIGHT="22.313682899722885"/>
<DICH_DATA CI_END="3.885745356526096" CI_START="0.009454070645523116" EFFECT_SIZE="0.19166666666666668" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5894743366963087" LOG_CI_START="-2.0243811567563723" LOG_EFFECT_SIZE="-0.7174534100300319" ORDER="113" O_E="0.0" SE="1.5353916556474716" STUDY_ID="STD-Watts-2003" TOTAL_1="47" TOTAL_2="45" VAR="2.3574275362318837" WEIGHT="8.764785427059726"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8471359943151472" CI_START="0.04419992005957584" DF="0.0" EFFECT_SIZE="0.19350282485875706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.07204686494711766" LOG_CI_START="-1.354578516119607" LOG_EFFECT_SIZE="-0.7133126905333622" NO="2" P_CHI2="1.0" P_Z="0.029245016388529384" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="137" WEIGHT="38.12509802233195" Z="2.1801679231582995">
<NAME>Valacyclovir</NAME>
<DICH_DATA CI_END="0.8471359943151474" CI_START="0.04419992005957582" EFFECT_SIZE="0.19350282485875706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.07204686494711755" LOG_CI_START="-1.3545785161196071" LOG_EFFECT_SIZE="-0.7133126905333622" ORDER="114" O_E="0.0" SE="0.7533654405327831" STUDY_ID="STD-Sheffield-2006" TOTAL_1="118" TOTAL_2="137" VAR="0.5675594869891543" WEIGHT="38.12509802233195"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2764149319260189" CI_END="12.134490348875781" CI_START="0.21861872163867616" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6287500630262692" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.0840215405922211" LOG_CI_START="-0.6603126495399358" LOG_EFFECT_SIZE="0.2118544455261425" METHOD="MH" NO="5" P_CHI2="0.5990607412399583" P_Q="0.0" P_Z="0.6340126714144534" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="367" WEIGHT="100.0" Z="0.4760866186593328">
<NAME>Neonatal viral detection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.047650060809763" CI_START="0.06187382785262341" EFFECT_SIZE="0.9649122807017544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1774686829658707" LOG_CI_START="-1.2084930153223656" LOG_EFFECT_SIZE="-0.015512166178247553" ORDER="115" O_E="0.0" SE="1.401525712275397" STUDY_ID="STD-Andrews-2006" TOTAL_1="57" TOTAL_2="55" VAR="1.964274322169059" WEIGHT="66.96415065799425"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="116" O_E="0.0" SE="0.0" STUDY_ID="STD-Scott-1996" TOTAL_1="27" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="72.26335242545869" CI_START="0.12242459021639576" EFFECT_SIZE="2.9743589743589745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8589181053928858" LOG_CI_START="-0.9121313409920473" LOG_EFFECT_SIZE="0.47339338220041927" ORDER="117" O_E="0.0" SE="1.6277281617224928" STUDY_ID="STD-Scott-2002" TOTAL_1="116" TOTAL_2="115" VAR="2.6494989684644854" WEIGHT="33.03584934200575"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="118" O_E="0.0" SE="0.0" STUDY_ID="STD-Sheffield-2006" TOTAL_1="170" TOTAL_2="168" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>